Blood Cancer Diagnostics

Global Blood Cancer Diagnostics Market to Reach US$14.4 Billion by 2030

The global market for Blood Cancer Diagnostics estimated at US$10.5 Billion in the year 2024, is expected to reach US$14.4 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Assay Kits and Reagents segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 8.8% CAGR

The Blood Cancer Diagnostics market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Blood Cancer Diagnostics Market – Key Trends & Drivers Summarized

Why Is Blood Cancer Diagnostics Becoming a Critical Focus in Oncology?

Blood cancer diagnostics have become an essential component of modern oncology, enabling early detection, disease classification, and personalized treatment planning for hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. As the global burden of blood cancers continues to rise, healthcare providers are prioritizing advancements in diagnostic technologies to improve survival rates and treatment outcomes. Blood cancers account for a significant portion of cancer-related deaths worldwide, making early and accurate detection crucial for timely intervention.

With the emergence of precision medicine and targeted therapies, the demand for high-sensitivity diagnostic tools has surged. Traditional diagnostic methods, including complete blood counts (CBC), bone marrow biopsies, and flow cytometry, are now being supplemented with advanced molecular and genetic testing. The integration of next-generation sequencing (NGS), liquid biopsy, and artificial intelligence (AI)-driven diagnostic algorithms is revolutionizing blood cancer detection, allowing for earlier diagnosis and more personalized treatment strategies. As the healthcare industry moves toward non-invasive, highly accurate diagnostic solutions, the market for blood cancer diagnostics is expected to grow rapidly.

How Are Technological Advancements Transforming Blood Cancer Diagnostics?

Significant advancements in molecular diagnostics, bioinformatics, and digital pathology are reshaping the landscape of blood cancer diagnostics, enabling faster, more precise, and less invasive detection methods. One of the most transformative innovations in this space is liquid biopsy, which allows for the detection of circulating tumor DNA (ctDNA) and other biomarkers in blood samples. Unlike traditional bone marrow biopsies, liquid biopsy offers a non-invasive alternative that can detect minimal residual disease (MRD) and monitor treatment response in real-time. This technology is particularly beneficial for patients with leukemia and lymphoma, where disease progression requires continuous monitoring.

Another major breakthrough in blood cancer diagnostics is the widespread adoption of next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based techniques. These molecular tools enable comprehensive genetic profiling, allowing oncologists to identify specific mutations and genetic aberrations associated with different types of blood cancer. AI-powered diagnostic algorithms are also enhancing the accuracy of hematopathology analysis, automating image recognition in blood smears and bone marrow aspirates to detect abnormal cell morphology with high precision. Furthermore, advancements in flow cytometry and immunophenotyping are improving the ability to distinguish between different subtypes of leukemia and lymphoma, facilitating more targeted treatment approaches. As these technological innovations continue to evolve, they are expected to improve early diagnosis, reduce misdiagnosis rates, and enhance overall patient management in hematologic oncology.

Which Market Trends Are Driving Growth in Blood Cancer Diagnostics?

The growing adoption of personalized medicine and targeted therapies is one of the most significant trends fueling the demand for advanced blood cancer diagnostics. With an increasing number of cancer treatments being designed to target specific genetic mutations, comprehensive molecular testing has become a critical step in treatment decision-making. This trend has led to the rapid expansion of companion diagnostics, where blood cancer patients undergo genetic testing to determine their eligibility for targeted therapies, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies.

Another key trend shaping the market is the increasing reliance on artificial intelligence and automation in cancer diagnostics. AI-powered image analysis tools are streamlining hematopathology workflows, reducing the time required for diagnosis while improving accuracy. Additionally, the expansion of decentralized testing and point-of-care diagnostics is making blood cancer detection more accessible, particularly in regions with limited healthcare infrastructure. The integration of cloud-based diagnostic platforms and telemedicine solutions is further enhancing remote diagnosis and patient monitoring, allowing oncologists to track disease progression more efficiently. As the global healthcare landscape shifts toward early cancer detection and preventive screening, the demand for innovative blood cancer diagnostics is expected to rise.

What Are the Key Growth Drivers Shaping the Future of the Blood Cancer Diagnostics Market?

The growth in the blood cancer diagnostics market is driven by multiple factors, including rising cancer prevalence, advancements in diagnostic technology, and increasing investments in precision oncology. One of the most significant drivers is the growing incidence of hematologic malignancies, which has led to a higher demand for early and accurate diagnostic solutions. According to the Leukemia & Lymphoma Society, blood cancers account for nearly 10% of all cancer diagnoses worldwide, underscoring the need for robust diagnostic infrastructure to improve detection and patient outcomes.

Another crucial driver shaping the market is the increasing focus on liquid biopsy and minimally invasive diagnostic techniques. With healthcare providers and patients seeking alternatives to traditional invasive procedures, liquid biopsy has emerged as a game-changer in blood cancer detection and monitoring. Additionally, government initiatives and funding for cancer research are accelerating the development of novel diagnostic platforms, further expanding market opportunities. The rise of biomarker-driven clinical trials and regulatory approvals for advanced diagnostics is also propelling growth, as pharmaceutical companies collaborate with diagnostic firms to develop companion tests for emerging therapies.

As the field of hematologic oncology continues to advance, the integration of AI, big data analytics, and molecular diagnostics will play a pivotal role in shaping the future of blood cancer diagnostics. The increasing availability of precision diagnostics, coupled with ongoing innovations in early detection and treatment monitoring, will drive significant growth in this market, ultimately improving survival rates and quality of life for blood cancer patients worldwide.

SCOPE OF STUDY:

The report analyzes the Blood Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Instruments, Assay Kits and Reagents); Test Type (Blood Tests, Imaging Tests, Biopsy, Molecular Test); End-Use (Hospitals and Clinics End-Use, Diagnostic Labs End-Use, Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• Abbott Laboratories
• Adaptive Biotechnologies
• Agilent Technologies, Inc.
• Alercell, Inc.
• Asuragen (a Bio-Techne brand)
• Becton, Dickinson and Company (BD)
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Foundation Medicine, Inc.
• GE HealthCare Technologies Inc.
• Grail, Inc.
• Guardant Health, Inc.
• HORIBA, Ltd.
• Illumina, Inc.
• InVivoScribe, Inc.
• QIAGEN N.V.
• Quest Diagnostics
• SkylineDx
• Sophia Genetics
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.